Labeling Multilingual Compliance – Best Practices for FDA & EMA

Introduction: Why Multilingual Labeling Matters in Global Clinical Trials

As clinical trials expand across borders, the need for sample labels in multiple languages has become essential. Accurate and compliant labeling not only ensures sample traceability and safe transport but also meets the regulatory requirements of country-specific authorities. Incorrect or poorly translated labels can lead to customs rejections, site confusion, or sample mismanagement—each of which can result in regulatory findings.

Both the FDA and EMA emphasize that labeling practices for clinical samples should be clear, unambiguous, and appropriate for the region in which the study is being conducted. Sponsors must ensure that labeling SOPs account for local language needs, translation controls, and consistent label design.

Regulatory Requirements for Sample Labeling

According to ICH E6(R2) and Annex 13 of the EU GMP Guidelines, labeling for investigational materials (including clinical samples) must:

• Be understandable to local staff (language requirements)
• Include key elements such as protocol ID, subject ID, sample type, and collection date
• Ensure the legibility and permanence of printed information
• Comply with national health authority requirements, including translation accuracy

In multi-regional trials, this means labels may need to be presented in English plus the local language (e.g., Spanish, French, Japanese), particularly for sample collection kits and shipping containers.

Common Labeling Non-Compliance Issues Identified in Inspections

• Missing local language translation on preprinted labels
• Incorrect label application or orientation (e.g., covering barcodes)
• Translation errors leading to misinterpretation (e.g., “serum” translated as “blood”)
• Inconsistent label formats across regions, causing confusion at central labs
• Use of abbreviations not standardized or explained

In a 2022 EMA inspection, a sponsor was cited for failing to provide sample labels in Hungarian, despite the study being conducted at three sites in Hungary. The deviation triggered a CAPA to revise the global labeling SOP and retrain study teams on country-specific requirements.

Best Practices for Multilingual Labeling Implementation

To avoid such findings, sponsors and CROs should adopt the following practices:

• Use a validated translation vendor with expertise in medical terminology
• Develop label templates that allow dynamic language switching
• Include both English and local language on each label where feasible
• Ensure that any barcodes remain scannable and unblocked
• Train site staff to interpret label content in both languages

Table: Labeling Elements and Language Guidance

CAPA Strategy for Labeling Deviations

When deviations are identified—such as using incorrect translations or applying outdated labels—CAPA should include:

• Immediate quarantine of mislabeled samples (if risk is significant)
• Label redesign and translation review
• Re-training of packaging staff and couriers
• Revision of the labeling SOP to include version control and verification steps
• Audit of remaining inventory to detect other affected labels

Tools and Templates for Global Labeling

Some sponsors use centralized labeling portals that offer:

• Drop-down options for language selection
• Pre-translated fields for sample types, handling instructions, and site-specific content
• Built-in label printing with 2D barcodes and sample-specific QR codes
• Version-controlled PDF archives for inspection review

These tools help reduce the risk of manual translation errors and improve efficiency across global study sites.

External Reference

For examples of multilingual label guidelines, refer to the EU Clinical Trials Register at clinicaltrialsregister.eu.

Conclusion

Multilingual labeling is an essential but often overlooked aspect of sample management in global trials. Sponsors must design robust SOPs and systems to ensure translations are accurate, label content is complete, and local requirements are met. With proactive CAPA frameworks and validated tools, organizations can reduce labeling-related non-compliance and improve inspection readiness across their clinical portfolio.

How to Label Investigational Products for Global Clinical Trials: Best Practices

Labeling investigational products (IP) for global study sites is one of the most critical and complex aspects of clinical trial supply management. Labels must meet country-specific regulatory guidelines while ensuring subject safety, blinding integrity, and traceability. In this tutorial, we cover the essential steps and best practices for designing and implementing compliant IP labels across international clinical sites.

The Purpose and Scope of IP Labeling:

Investigational product labels provide key information to study participants and site personnel. They help ensure correct usage, blinding, and storage of the product throughout the study. As per USFDA and EMA guidance, improper labeling is a major regulatory concern and can jeopardize trial integrity.

Core Objectives of IP Labeling:

• Compliance with local regulatory requirements
• Ensuring participant safety
• Maintaining the blind and randomization codes
• Facilitating traceability and accountability

Standard Content Required on IP Labels:

While specific content may vary by region, several universal elements are expected in any IP label:

• Protocol number and study title
• Unique product code or identifier
• Randomization/blinding codes (if applicable)
• Storage conditions (e.g., “Store between 2°C–8°C”)
• Expiry or retest date
• Dosage instructions or cautionary statements
• Site address or shipment location
• Statements like “For Clinical Trial Use Only”

Global Regulatory Labeling Requirements:

Labeling requirements vary across regulatory jurisdictions. It is essential to harmonize them while customizing for country-specific elements.

Examples of Country-Specific Labeling Rules:

1. USFDA: IP label must include sponsor information and the IND number.
2. CDSCO (India): Requires labeling in English and Hindi or local language, along with approval reference numbers.
3. EMA: Dual language labeling may be mandatory for EU countries. Storage and expiry must be prominently displayed.

To learn how regulatory expectations impact label stability, visit Stability Studies.

Multilingual Labeling and Translation:

Labels in multinational trials must often be printed in multiple languages to meet local requirements. However, the risk of translation errors must be mitigated through validated processes.

Best Practices for Translation:

• Use qualified, professional medical translators
• Apply back-translation techniques for verification
• Involve local regulatory experts to confirm accuracy
• Document all translation workflows for audit readiness

Label Design and Blinding Considerations:

Designing IP labels involves not just compliance, but also maintaining blinding and logistical efficiency. For blinded studies, labels must not disclose treatment group or product identifiers.

Design Strategies for Blinded Labels:

• Use identical labels for active and placebo products
• Assign anonymized kit codes with randomization systems
• Include barcodes or QR codes for digital tracking
• Use tamper-evident label materials

For aligning with GMP principles during labeling, see GMP documentation.

Label Printing, Inspection, and Reconciliation:

Once label text and layout are approved, printing must follow validated processes. Each batch should undergo a thorough inspection before use.

Checklist for Labeling Operations:

1. Approved label text version in system
2. Quality-approved label template and format
3. Validated label printers and software
4. Reconciliation of printed vs. used labels
5. Destruction log for unused/damaged labels

Label Accountability at Site Level:

Study sites must log all IP label usage, including receipt, application, and destruction. Site Initiation Visits (SIVs) must include label SOP training.

Ensure compliance with SOP writing in pharma to meet site accountability standards.

Label Change Control and Documentation:

Any change in IP label text, layout, or format requires a documented change control. All changes must be approved by QA and tracked using version control.

Documenting Label Changes:

• Initiate change request with justification
• Assess regulatory implications
• Update label version and inform all sites
• Archive superseded label versions securely

Quality Assurance and Regulatory Audits:

Regulatory bodies such as ANVISA and MHRA expect complete traceability and compliance in labeling practices. Regular audits ensure that sponsor and site practices align with GCP and GMP.

Audit Readiness Tips:

• Maintain version-controlled label files
• Archive all translation validations
• Retain batch-specific label reconciliation records
• Document training records for label-related SOPs

Conclusion:

Effective investigational product labeling across global study sites requires meticulous planning, regulatory understanding, and operational control. By standardizing label content, maintaining multilingual accuracy, and integrating QA oversight, sponsors can ensure compliance and trial success. Leveraging best practices also minimizes the risk of regulatory findings, safeguarding both data integrity and patient safety.